Advertisement
Canada markets open in 6 hours 34 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7266
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    83.83
    +1.10 (+1.33%)
     

  • Bitcoin CAD

    88,860.88
    +4,801.27 (+5.71%)
     

  • CMC Crypto 200

    1,299.09
    -13.53 (-1.03%)
     

  • GOLD FUTURES

    2,396.30
    -1.70 (-0.07%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,431.00
    -116.25 (-0.66%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

Reuters
A sample of Botox is seen at the Long Island Plastic Surgical Group at the Americana Manhasset luxury shopping destination in Manhasset, New York September 30, 2010. REUTERS/Shannon Stapleton

(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill.

Allergan on Tuesday night said its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company.

"We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday.

(Reporting by Caroline Humer; Editing by Chizu Nomiyama)